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Abstract
Background: Neurocognitive deficits (NCDs) and associated meta-cognition difficulties associated with chronic
substance use often delay the learning and change process necessary for addiction recovery and relapse
prevention. However, very few cognitive remediation programs have been developed to target NCDs and metacognition for substance users. The study described herein aims to investigate the efficacy of a multi-component
neurocognitive rehabilitation and awareness program termed “Neurocognitive Empowerment for Addiction
Treatment” (NEAT). NEAT is a fully manualized, cartoon-based intervention involving psychoeducation, cognitive
practice, and compensatory strategies relevant across 10 major cognitive domains, including aspects of attention,
memory, executive functions, and decision-making.
Method/design: In a single-blind randomized controlled trial (RCT), 80 female opioid and/or methamphetamine
users will be recruited from an addiction recovery program providing an alternative to incarceration for women
with substance use-related offenses. Eight groups of 9–12 participants will be randomized into NEAT or treatmentas-usual (TAU). NEAT involves 14 90-min sessions, delivered twice weekly. The primary outcome is change in selfreported drug craving from before to after intervention using Obsessive Compulsive Drug Use Scale. Secondary and
exploratory outcomes include additional psychological, neurocognitive, and structural and functional neuroimaging
measures. Clinical measures will be performed at five time points (pre- and post-intervention, 3-, 6-, and 12-month
follow-up); neuroimaging measures will be completed at pre- and post-intervention.
Discussion: The present RCT is the first study to examine the efficacy of an adjunctive neurocognitive rehabilitation
and awareness program for addiction. Results from this study will provide initial information concerning potential
clinical efficacy of the treatment, as well as delineate neural mechanisms potentially targeted by this novel
intervention.
Trial registration: ClinicalTrials.gov NCT03922646. Registered on 22 April 2019
Keywords: Opioid, Methamphetamine, Neurocognitive deficits, Meta-cognition, Rehabilitation, Awareness,
Addiction, Substance use disorder, Diversion program, Women

* Correspondence: hekhtiari@laureateinstitute.org
1
Laureate Institute for Brain Research, 6655 South Yale Ave., Tulsa, OK 74136,
USA
Full list of author information is available at the end of the article
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.

Ekhtiari et al. Trials

(2021) 22:330

Background
Opioid use disorder (OUD) and methamphetamine use
disorder (MUD) are among the costliest mental health
disorders in the USA and worldwide [1, 2]. Opioids (including prescription pain relievers and the illicit drug
heroin) were involved in more than 42,000 deaths in the
USA in 2016, more than any year on record [3]. This accounts for more deaths than road accidents and gun violence combined. In 2017, amphetamine use disorders
were reported as the second most common use disorders worldwide by the United Nations Office on Drugs
and Crimes (UNODC) [4]. Even more alarming, the
number of overdoses with heroin and methamphetamine
has tripled from 2011 to 2016 [5].
Chronic OUD and MUD are associated with numerous other mental health symptoms, including anxiety
and depression [6, 7], as well as subjective and objective
neural and cognitive deficits. These neurocognitive deficits (NCDs) are apparent across domains of memory, attention, decision-making, judgment, negative affect,
metacognition, self-regulation, and impulse inhibition
[8–10]. Neuroimaging studies indicate that these deficits
may relate to dysfunction within a broad network of the
brain regions, including the prefrontal cortex, orbitofrontal cortex, amygdala, nucleus accumbens, hippocampus, and anterior cingulate gyrus [11–13]. Maladaptive
neural changes in these regions result in aberrant salience attribution, increased reward expectancy, changed
learning pattern (including conditioned-incentive learning, habit learning, declarative learning), and impulsive
decision-making [13].
Current treatment programs for OUDs and MUDs are
mainly focused on abstinence from illicit drugs, with the
assumption that the NCDs will be subsequently restored.
However, NCDs are found to persist or sometimes even
become exacerbated after long-term abstinence and are
thought to contribute to relapse, decreased quality of
life, and/or lack of reintegration into society [14]. Furthermore, NCDs (particularly those related to attention
and memory) are considered a potential predictor for
treatment outcomes for either the core substance use
disorder or co-occurring symptoms (i.e., cognitivebehavioral therapies) [15, 16].
Numerous cognitive rehabilitation programs have been
developed to focus on compensatory strategies and restorative exercises for NCDs associated with traumatic
brain injuries [17], stroke [18], multiple sclerosis [19],
and schizophrenia [20]. These programs have consistently been found to improve functioning and long-term
outcomes for these groups of patients. There have been
a few preliminary attempts to transplant cognitive rehabilitation programs for use with substance use populations, providing initial evidence that such programs
could be beneficial. However, these programs did not
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explicitly link the cognitive rehabilitation modules to the
processes involved in addiction and recovery. There is
potential value in clarifying how such strategies may relate to the current neuroscientific understanding of addiction and recovery, as well as the co-occurring
symptoms often experienced.
The present pilot study aims to characterize the clinical potential for an intervention targeting NCDs in
OUDs and MUDs by enhancing awareness and use of
neurocognitive skills in the context of substance use recovery. This aim will be accomplished by randomizing
subjects who are already enrolled in substance use treatment to complete a novel “Neurocognitive Empowerment for Addiction Treatment” (NEAT) program or
treatment-as-usual intervention. NEAT is novel in (a) its
use of cartoons, brain awareness games, and real-life scenarios to ensure it is interactive and engaging; (b) its
focus on the role of neurocognitive deficits in recovery
from substance use and co-occurring mental health
symptomatology; and (c) its incorporation of neuroscience findings specific to substance use.
The primary outcome in this trial is “change in selfreported drug craving from baseline to after intervention
using the Obsessive Compulsive Drug Use Scale (total
score) [21]. Secondary outcome is the mean change in
self-report subjective cognitive functioning from baseline
to after intervention using PROMIS Cog Abilities [22]
and PROMIS Cog General measures [22]. Exploratory
outcomes include additional psychological, neurocognitive, and structural and functional neuroimaging measures and are available on ClinicalTrials.gov. We
hypothesis that as compared to the active control, the
NEAT program will be associated with the following:
1. Greater reduction in self-report drug carving symptom from before to after intervention (primary
outcome)
2. Enhanced subjective cognitive functioning from
before to after intervention (secondary outcome)
3. Improved objective neuropsychological functioning
from before to after intervention
4. Reduced mental health (i.e., depression and anxiety)
symptoms from before to after intervention and
other follow-up time points
5. Lower number of relapses as measured with urine
drug tests during follow-up time points
6. Decreases in subcortical limbic (amygdala and
ventral striatum) activation and increase prefrontal
cortical top-down inhibitory activation during induced drug craving in fMRI drug cue reactivity
from before to after intervention
7. Increases in cortical gray matter density (measured
with voxel-wise brain morphometry) and white
matter track integrity (measured with fractional
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anisotropy) in areas related to self-control and
awareness, including prefrontal gray matter and
frontostriatal/frontoamygdalar white matter from
before to after intervention
Outcome measures 3 to 7 are exploratory.

Methods/design
Study objectives

The present study aims to (a) determine the potential
clinical impact of the NEAT program on clinical symptoms and function, from pre- to post-intervention and at
long-term follow-up (12 months after treatment completion), and (b) explore the potential impact of the NEAT
program on functional and structural brain recovery,
from pre- to post-intervention.
Research environment/context

The present trial is conducted by Laureate Institute for
Brain Research (LIBR), and participants are recruited
from a single site, the Women in Recovery (WIR) program at Family and Children’s Services located in Tulsa,
OK. WIR is an intensive outpatient alternative for eligible women facing long prison sentences for nonviolent drug-related offenses.
Design

This is an assessor-blinded, two-arm, parallel-group,
randomized controlled clinical trial formulated in accordance with the Consolidated Standards of Reporting
Trials (CONSORT) 2010 guidelines (supplementary file
1). This protocol was written using the Standard Protocol Items: Recommendations for Interventional Trials
(SPIRIT) guidelines, and the SPIRIT checklist is provided in supplementary file 2. Eighty participants will be
recruited in eight groups. Groups will be randomly allocated to the intervention (n = 40) and control (n = 40)
groups in blocks of 4 in a 1:1 ratio. All 80 participants
will receive treatment-as-usual (TAU). Those subjects allocated to the intervention group will receive TAU but
will complete NEAT in lieu of nonessential aspects of
the TAU program that do not explicitly target neurocognitive function (e.g., culinary or legal education classes).
Thus, both NEAT and TAU groups received similar
amount (e.g., intensity, duration, frequency) of intervention. Self-report, interview-based, and neuroimaging assessments will be performed before (pre; week 0), during
intervention (from week 1 to week 7), after the intervention period (post; week 8), and/or after a follow-up
period (3, 6, 12 months; weeks 20, 32, 56, respectively).
Interview-based assessments were conducted by a
trained clinical practitioner blind to the allocation of
participants. Figure 1 summarizes the full design of the
trial in accordance with the CONSORT flow diagram.

Fig. 1 CONSORT flow diagram. The flow chart depicts participant
progression through the study from the initial enrolment to
allocation, follow-up, and finally analyses of their data stages.
Planned sample size, n = 64; to be enrolled, n = 80. Forty participants
will be enrolled in each arm (expected to be 8 dropouts in each
arm from pre- to post-intervention on average)

The trial was approved by the Western Institutional
Review Board (approval number: 20181028, 1-11414031) and registered in ClinicalTrials.gov on 22 April 2019
with NCT03922646 as ClinicalTrials.gov identifier no.;
amendments have been made to the protocol since the
original submission to ClinicalTrials.gov. The study is
funded by the Oklahoma Center for Advancement of
Science and Technologies (OCAST) Hamed Ekhtiari
[HE], principal investigator [PI], and Robin Aupperle
[RA] as co-investigator [CI].
As this study is considered a “no or minimum risk”
trial, there is no independent data monitoring committee
(DMC) assigned for this trial. Trial investigators will
monitor the data collection process, fidelity of the intervention, and integrity of protocol implementation on
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regular weekly basis meetings with the research staff.
There is no plan for interim analyses, and there are no
anticipated formal stopping rules for the trial as there
are no anticipated problems that could be detrimental to
the participants or the study integrity. The data that will
be collected in this study will be available from the principal investigator on reasonable request.
Participants
Inclusion criteria

To participate in this trial, subjects must (1) be 18 and
55 years old; (2) enrolled in WIR within 6 months; (3)
diagnosed with OUD and/or MUD (based on the MiniInternational Neuropsychiatric Interview (MINI) diagnostic interview for DSM-5 [23]) over the last 12
months; (4) be able to provide written informed consent;
(5) have sufficient proficiency in the English language to
understand and complete interviews, questionnaires, and
all other study procedures; and (6) have completed at
least an 8th grade education, to help facilitate the ability
to engage in the written materials included in the NEAT
program.
Exclusion criteria

Potential subjects will be excluded if they (1) are reluctant or unable to complete any of the major aspects of
the study protocol, including self-report or behavioral
assessment; (2) have uncorrectable vision or hearing
problems that would interfere with the completion of
the study procedures; (3) have diagnoses of schizophrenia spectrum or other psychotic disorders; (4) have
current mental or physical health symptoms that require
immediate attention (such as suicidal ideation with intent or plan, active psychotic symptoms, delirium); (5)
have a history of unstable liver or renal insufficiency;
glaucoma; significant and unstable cardiac, vascular,
pulmonary, gastrointestinal, endocrine, neurologic,
hematologic, rheumatologic, or metabolic disturbance;
or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or
that could prevent, limit, or confound the protocolspecified assessments; (6) have a positive test for drugs
of abuse at the time of baseline assessment, including
alcohol, cocaine, marijuana, opiates, amphetamines,
methamphetamines, phencyclidine, benzodiazepines,
barbiturates, methadone, and oxycodone; (7) have MRI
contraindications; and (8) have moderate to severe traumatic brain injury (loss of consciousness for less than
30 min or > 24 h posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits,
neurological disorders, or severe or unstable medical
conditions that might be compromised by participation
in the study. There is no limitation in the medications
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that participants could receive before, during, and after
intervention. However, the list of medication will be recorded for exploratory analysis.
Sample size calculation

With total enrollment of N = 80 and an estimated 20%
attrition rate, we anticipate having complete data at our
primary endpoint (post-treatment) for 32 subjects per
group or 64 in total. Due to cluster randomization, the
effective sample size will be n = (mk)/[1 + ρ(m − 1)]
where m, k, ρ are the number of subjects per cluster, the
number of clusters, and the intra-cluster correlation, respectively [24]; here, k = 4, and on average, m= 8 (80% of
10) per cluster. Considering a range of 0.05 to 0.3 for ρ,
nEff will be somewhere between 10.3 and 23.7 per group.
This effective sample size will provide a precision of
tn-1,1-α/2/√n or 0.43–0.70, times standard deviation as
margin of error at 95% confidence for a continuous
measure (self-reported drug craving), and 80% power to
detect large effect sizes (d = 0.83 to 1.3) for group differences in pre to post or pre to follow-up changes at a
two-sided 5% significance of a 2-sample t test. While we
may be underpowered to detect small to medium effects,
the current pilot study will be crucial for informing the
viability of the intervention and for estimating power for
future, larger clinical trials.
Recruitment

Study participants will be recruited through the WIR
program at Family and Children’s Services. Flyers will be
provided to the clinic program staff to be given to potential subjects. The research team may also discuss the
study to the groups of patients (i.e., when gathered for a
class). The research team will be available at WIR on a
regular basis to discuss the study privately with subjects
interested in the study. The WIR staff will not be
present during these individual meetings in order to increase confidentiality and ensure that subjects are making an informed decision to participate. All efforts will
be made to ensure that the recruited subject population
closely resembles the ethnic and racial composition of
the WIR program. The enrolled participants then will
give a written informed consent to one of the principle
investigators (PI) or research coordinator (RC) in a private interview/exam room at LIBR or WIR. Family
members will be allowed to be present and discuss the
consenting process with the participant if requested. In
this session, it will be emphasized that participation is
strictly voluntary and that they have the right to withdraw at any time without penalty. It will be emphasized
that the information provided during the course of the
study will have no impact on participants’ treatment and
care provided by WIR or other programs and clinics,
their experience at correctional facilities, or on any court
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processes or decisions. Follow-up meetings with the
WIR staff and directors will be held to make sure the
reasonable number of recruitments will happen to meet
the planned sample size.
Note that participants will be monetarily compensated for their time of participation in self-report,
behavioral, and neuroimaging assessment. Each participant will be also provided with a gift card ($10–15
per session) to compensate completing intervention
session assessments.
There are three follow-up assessment sessions 3, 6,
and 12 months after completion of the intervention with
urine drug test and questionnaires. Participants will be
compensated for their time for the follow-up assessments as well.
Randomization and blinding

All consented participants will receive NEAT or other
active, but non-essential regularly scheduled programming at WIR coinciding with the same timeframe.
Randomization will be happening in the group level, and
groups of 9–12 participants will be randomly allocated to
intervention conditions (study arms). This randomization
will be conducted in blocks of 4 groups. The
randomization will be determined prior to enrolling any
subjects using computer-generated allocations.
The randomization codes will be generated by a statistician not involved in enrollment or delivery of interventions and will be kept in a secure computer file with
controlled access. The research staff involved in the
conduct of interview-based assessments (e.g., MINI,
PRISM-5) will be blinded to the intervention condition.
Participants and all research staff are kept blind to their
intervention condition until completion of all baseline
assessments. However, due to the nature of the intervention, participants and research staff involved in providing
interventions will not be kept blind to the interventions
after completion of baseline assessments. Research investigators (who are unblinded) will be involved in both
delivering the intervention and doing the data analysis;
therefore, outcome analysis will not be blinded.
Treatment-as-usual

All participants will complete the essential components
of the WIR treatment program. The WIR program includes daily and weekly clinical visits and both individual
and group sessions. These sessions include but are not
limited to cognitive behavioral therapy, cognitive processing therapy, motivational interviewing, behavioral
modification and strength-based case management interventions, nutritional education, and occupational training. The WIR program is conducted in three phases,
with increasing independence at each phase (e.g., supervised probation with ankle monitor and residing in
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program-supervised housing at first; independent housing, independent employment, and outpatient visits multiple times per week towards the end of the program).
Phase 1 includes 40 structured hours weekly that is
devoted to addiction and trauma treatment, parent education, job readiness training, life skills, safe group housing, education, and community volunteering. Phase 2
includes 24 structured hours weekly that is devoted to
job retention training, part-time job replacement,
parent-child visitation, health and wellness services, education groups, subsidized housing, financial literacy, and
recovery support. Phase 3 includes 12 structured hours
weekly that considered full-time employment, parentchild reunification, education groups, independent
housing, recovery support technology, and community
integration. Graduation from the program occurs after
completion of phase 3, an average of 17 months in the
program. Random drug testing is conducted by WIR
throughout participation in the program. After graduation, women can continue participating in group programming on a volunteer basis. Implementing active or
active-control interventions will not require alteration to
treatment-as-usual.
Interventions
Active control intervention

Participants in the comparison group will receive the essential components of the WIR program (TAU) plus
additional WIR training sessions related to health and
wellness, communication skills, and/or financial literacy,
scheduled at the same days/times as the NEAT sessions.
Thus, the active control intervention has the same duration and frequency as the active intervention without
involving the cognitive training content designed for the
active intervention.
Active intervention

The active intervention in this trial, the Neurocognitive
Empowerment for Addiction Treatment (NEAT), was
developed to target cognitive domain thoughts to be either influenced by substance use or involved in drug
craving and seeking behavior based on the dynamic
model of craving (DCM) (Rezapour et al. [25]). According to the DCM model (Fig. 2) which has been inspired
by the traditional cognitive behavioral therapy frameworks [26], drug craving is triggered by environmental
cues (E) (including both internal and external cues).
These cues then elicit distinct yet collaborative bottomup and top-down attentional processes that increase the
focus of attention on drug-relevant cues (A). This attentional deployment activates saliency evaluation processes
(S) related to drug-associated cues. The retrieval of
memories (M) linked to the drug cues provides relevant
information during saliency processing. Saliency
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planning. NEAT will target the cognitive domains shown
in Fig. 3 through the use of the following five
components:

Fig. 2 Dynamic model of craving (DCM). A neuroscience-informed
conceptual framework to define the major cognitive targets in the
dynamic response to drug-related or emotionally salient cues that
can end up to drug-seeking and consumption behaviors. E,
environment; A, attention, S, saliency processing; M, memory; I,
interoception; Co, control; R, response

evaluation can result in an interoceptive state that
represents the subjective feeling of craving, leading to
the engagement of executive control (Co) and
decision-making processes to execute actions supporting drug-taking behavior or abstinence. In targeting
these functions, NEAT also provides skills important
for daily functioning and re-integration into the society, including self-monitoring, time management, and
problem solving [27].
NEAT consists of 14 90-min group sessions, which
will be led by two trained master’s level therapists or
therapists-in-training (e.g., doctoral students in clinical
psychology) supervised by a licensed clinical psychologist
(RLA). Groups are led by therapists according to the
session-by-session manual. All sessions will be audiorecorded to support supervision and fidelity of implementation. Cartoon-based treatment binders and brain
planners are provided to all participants. As the intervention is designed to be delivered in the group therapy
setting during the trial and also in future clinical use,
clustering of the effect due to the group administration
of the intervention is not accounted as a variable of
interest.
Each session starts with a didactic, psychoeducation
portion describing the concepts and skills of focus in
each session. The session is followed by a written material with descriptions of the concepts/skills in verbal and
pictorial (cartoon) formats. The session continues with
practicing cognitive tasks/games relevant for each skill
and ends with a discussion of how they can monitor and
practice each skill in their everyday life. Besides the insession components, subjects are provided with homework material to practice the learned objectives between
sessions, including monitoring their use of various brain
functions, implementing compensatory strategies, and
completing additional cognitive exercises. They are also
asked to complete aspects of the brain planner between
each session, starting with the retrospective recording of
events and slowly progressing towards prospective

1. Neuroscience-informed psychoeducation: The main
purpose of the neuroscience-informed psychoeducation component is to promote subjects’ awareness
about the cognitive impairments often associated
with drug craving and addiction. Participants are
provided with information concerning the common
behavioral manifestations of these impairments in
daily life activities. They are informed about lifestyle
changes (e.g., nutrition, physical exercise, sleep) that
can facilitate brain recovery. To improve learning
and consolidation, the education components are
accompanied by colorful and comic cartoons [28].
2. Cognitive exercises: According to previous work,
using cognitive exercises with game-like features
can be useful for supporting treatment engagement
and restoration of cognitive functions among people
with SUDs [29]. These game-based exercises include such things as Stroop-like tasks [30], spot the
differences game [31], and target cancelation tasks
[32]. In NEAT, these games are used not only as a
way of practicing and improving specific brain functions, but also for enhancing understanding of the
brain functions discussed (e.g., as a way of demonstrating what is meant by “inhibition” or “working
memory”) and supporting metacognitive awareness
(the next component).
3. Metacognitive training: Metacognition awareness
[33, 34] is supported through self-monitoring in between sessions and group discussions about the
cognitive functions involved in each brain exercise
and the role that these functions (and the associated
compensatory strategies) play in their day-to-day
functioning, craving management, and substance
use recovery. This component targets insight towards the cognitive foundations of the training program and aims to enhance motivation to implement
skills and generalization of learning.
4. Compensatory strategies: The main purpose of
these components is to provide specific cognitive
strategies for supporting optimal cognitive
functioning and compensating for deficits. For
example, providing mnemonic aids and goal
management training for memory- and planningrelated problems [35, 36]. These components are
integrated with the cognitive exercises discussed
above to provide a thorough understanding and
awareness of the role of specific cognitive functions
in their lives.
5. Brain planner: Training participants to keep records
of their daily activities, including both
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Fig. 3 Architecture of Neurocognitive Empowerment for Addiction Treatment (NEAT) for 14 sessions. In each session, a new cognitive domain is
added to the previous one in trainings and exercises (accumulative architecture). The brightness of color indicates the level of complexity of the
cognitive modules. The basic modules (e.g., sustained attention) marked with bright colors, and the complex ones marked with dark colors
(e.g., monitoring)

retrospectively (e.g., recording past events) and
prospectively (e.g., planning future activities and
goals), is another critical aspect of NEAT. Planner
use can support optimal daily functioning and the
use of higher-order cognitive functions such as selfmonitoring and planning (which are also supported
by compensatory strategies discussed above) but
can also help compensate for deficits in these cognitive domains and others (i.e., memory deficits) [37].
The use of a planner also supports compliance with
NEAT and other substance use treatment activities.
Each training session of NEAT has time dedicated
to learning and practicing using the planner.
Based on the nature of the intervention, there are
no anticipated serious adverse events (SAEs), adverse
events (AEs), or harms from the intervention. In case
of any minimum AEs during the assessments or intervention, the study investigators will be involved to
mitigate any risks or consequences and the details

will be documented and reported to the LIBR leadership team and the IRB committee (WIRB) according
to the WIRB protocols. The reason for dropout for
participants who discontinue or deviate from the
intervention protocols will be collected for further exploratory analyses.
Measures

Table 1 indicates the list of self-report, behavioral, and
neuroimaging assessments included in the protocol
(refer to Fig. 4 for the timing of assessments). We will
use the total score of the Obsessive Compulsive Drug
Use Scale (OCDUS) [21] as a primary outcome measure
for drug craving in the past week. It is a 12-item questionnaire consisting of three factors including thoughts
about drugs and interference, desire and control, and resistance against thoughts and intention to use drugs that
compose a total score. The remaining questionnaires
and tasks used as secondary and exploratory outcome
measures are described in Fig. 4.
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Table 1 Diagnostic, demographic, self-report, behavioral, and neuroimaging assessments
Diagnostic and demographic assessment
Diagnosis

MINI V6.0 [23] or the PRISM-5

History

Assessment of medication history and medication and therapy compliance

Standard self-report scales
Substance use

Obsessive Compulsive Drug Use Scale (OCDUS) [21]

Substance use

Customary Drinking and Drug Use Record (CDDR) [38]

Substance use

Addiction Severity Index (ASI) [39]

Substance use

Desire for Drug Questionnaire (DDQ) [21]

Substance use

PROMIS Alcohol Use [40]

Substance use

PROMIS Nicotine Dependence [41]

Substance use

PROMIS Substance Use Severity [42]

Mental health

PROMIS Adaptive Scales (depression, anxiety, and anger) [43]

Mental health

Traumatic Events Questionnaire (TEQ) [44]

Mental health

Difficulties in Emotion Regulation Scale (DERS) [45]

Mental health

UPPS Impulsive Behavior Scale [46]

Mental health

Behavioral Inhibition System/Behavioral Approach Scale (BIS/BAS) [47]

Treatment engagement

Services Engagement Scale (SES) [2]

Treatment engagement

Client Evaluation of Self and Treatment (CEST) Engagement [48]

Feasibility/knowledge

Credibility/Expectancy Questionnaire (CEQ) [48]

Feasibility/knowledge

Homework Rating Scale (HRS) [49]

Feasibility/knowledge

Working Alliance Inventory (WAI) [50]

Cognitive functions (subjective)

PROMIS Cog Abilities (PROMIS-CA) [22]

Cognitive functions (subjective)

PROMIS Cog General (PROMIS-CG) [22]

Behavioral assessment
Neuropsychological

NIH Toolbox Cognitive Assessment Battery [51]

Neuropsychological

Iowa GamblingTask [52]

Neuropsychological

Delayed Discounting [53]

Neuropsychological

Emotional and Classic Go/NoGoTasks [54]

Neuropsychological

Classic version of the go/no-go task [55]

Neuroimaging assessments
Neuroimaging

T1-W sagittal MP-RAGE

Neuroimaging

fMRI resting state

Neuroimaging

fMRI monetary incentive delay [56]

Neuroimaging

fMRI stop signal [57]

Neuroimaging

fMRI drug cue reactivity [58]

Neuroimaging

T2-W sagittal

Neuroimaging

T2-W axial FLAIR

Neuroimaging

Diffusion tensor imaging

Laboratory assessments
Substance use

Urine drug test

Biomarker assessment

Blood sample test

Biological specimens (blood and oral and mouth
microbiome) data will be collected in the baseline for
further exploratory analysis on the predictive role of biomarkers on response to interventions. Less than 150 mL

of blood will be collected per subject, which is well
within the safety limit of ~ 450 mL per blood draw.
Blood will not be drawn from subjects with a hematocrit
below 30%. A trained phlebotomist will obtain blood
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Fig. 4 Schedule of enrollment, interventions, and assessments. This figure indicates the assessments or interventions completed for screening,
pre-intervention, weekly during the completion of the intervention, post-intervention, and 3- and 6-month follow-up. Participants are randomized
in groups of 9–12 to complete either neuroscience-informed psychoeducation (NEAT) or active control intervention. OCDUS, Obsessive
Compulsive Drug Use Scale; ASI, Addiction Severity Index; CDDR, Customary Drinking and Drug Use Record; DDQ, Desire for Drug Questionnaire;
TEQ, Traumatic Events Questionnaire; BIS/BAS, Behavioral Inhibition System/Behavioral Approach Scale; UPPS-P, UPPS Impulsive Behavior Scale;
DERS, Difficulties in Emotion Regulation Scale; PROMIS, Patient-Reported Outcomes Measurement Information System; SES, Services Engagement
Scale; CEST, Client Evaluation of Self and Treatment; HRS, Homework Rating Scale; WAI, Working Alliance Inventory; PROMIS-CA, PROMIS Cog
Abilities; PROMIS-CG, PROMIS Cog General

samples in the morning of one of the visits, or at a time
convenient for the participant. Participants will also be
asked to provide microbial samples during the biomarker session.
For blood samples, plasma, serum, PBMCs, and
genetics will be transported to and processed at the
University of Oklahoma Integrative Immunology Center (IIC) Laboratories. Plasma, serum, and genetic
samples will be stored in secure freezers at − 80 °C.
Freezers will be maintained in a specially equipped
room with emergency backup power and an automated telephone alarm system that is programmed to
call in case of failure. Additional aliquots of samples
will be stored at − 80 °C should repeat analyses be required at a later date. PBMCs will be stored in liquid
nitrogen dewars with liquid level monitors and alarms
in a secure room at the University of Oklahoma IIC
Laboratories.
Participants will also be asked to provide microbial
samples during the biomarker session. All participants
will be asked to provide forehead, mouth, and stool
samples. A research assistant will provide the participant with an all-in-one sample collection kit system
for collecting, stabilizing, transporting, and purifying
samples which include cotton swabs, tubes labeled by
body area, and a one-page sheet with step-by-step instructions. Once a participant has obtained all samples and provided them to the research assistant, the
research assistant will label each tube with the

subject’s ID number and date of sample. Once the
sample has been properly labeled, it will be placed in
a freezer in a locked office. The microbiome samples
will be transported to the University of Oklahoma IIC
Laboratory for DNA extraction and long-term storage
in secure freezers at − 80 °C. Analysis of the deidentified samples will be conducted at the University
of California-San Diego.
Data management

Confidentiality will be maintained by keeping identifying
information (such as names and phone numbers) in secure servers. Except for a contact form, research data
will be identified by a subject number rather than by
name. An alpha numeric system will be used for the
identification of subjects. All hard copies of study information will be kept in locked file cabinets inside a
locked office. All electronic study information will be
stored on secure servers with appropriate access controls. Only study personnel will have access to the
identifying data. The WIR staff will be aware of who
is participating in the research study, as they will
know who is attending this group versus the other
WIR activities planned at that time. In addition, these
treatment providers may insert into their treatment
records that they attended these treatment sessions.
However, treatment program staff will not be privy to
any of the information provided to the research study
personnel via interview, behavioral, or self-report
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assessments. Subject identity will not be disclosed to
any person who is not authorized to see this information,
except in the event of a medical emergency or if required
by law. Paper copies of consents, screening forms, the research privacy form and any other forms, and testing results or papers containing personally identifiable
information (PII) will be stored in locked cabinets at the
Laureate Institute for Brain Research (LIBR). Any electronic data will have all identifiable information encrypted
and be stored on a password-protected database on a secure server managed by LIBR.
Participants will be told that their information provided during the course of the study will remain confidential within the research study team. However, given
the nature of the treatment groups held at WIR, confidentiality concerning their participation in the study
cannot be guaranteed. Family members will be allowed
to be present and discuss the consenting process with
the participant if requested. The consent mentions the
biological samples collected in this study will be stored
for future research. Participants are also informed that
the data collected as part of this study, including interviews and medical information, research test results, and
biological specimens, may be shared with collaborators
(researchers at other nonprofit research institutions,
government or commercial organizations), and any data
shared will not include the name or other personally
identifiable information. The consent form is available
from the corresponding author on request. Additionally,
Certificates of Confidentiality (CoCs) will be asked from
the National Institute of Health (NIH) to protect the
privacy of research subjects by prohibiting disclosure of
identifiable, sensitive research information to anyone not
connected to the research except when the subject consents or in a few other specific situations.
Statistical analysis

Categorical variables will be summarized by frequency and
proportion, and continuous variables by mean and standard
deviation (SD), or by median and inter-quartile range if the
distribution, appeared skewed even after simple (e.g., log)
transformations, for all participants and for participants in
each treatment arm. Data normality will be evaluated by
quantile-quantile (QQ) plot and Shapiro-Wilk test.
Treatment effects will be compared by the intentionto-treat (ITT) principle, i.e., all subjects who were randomized will be included in the final analysis, regardless
of their adherence to any of the interventions. In order
to detect changes in the variables recorded for the
primary and secondary outcomes, mixed-effects model
analyses will be performed using fixed-effects of time
(pre-, post-intervention time points) as a within-subject
factor and condition (intervention vs. control) as a
between-subject factor; within-subject dependency will
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be captured by either random cluster and/or subject intercepts or within-subject correlation structure (e.g., 1storder autoregressive or exponential power), whichever
Akaike or Bayesian information criterion (AIC or BIC)
favor. Mixed-effects models allow using all available observations and, without the need of imputation, provide
unbiased estimates under the missing at random mechanism, a plausible assumption for randomized trials, and
are known to be more powerful than any ad hoc imputation [59]. We include age and IQ as covariates. The inclusion of other covariates will be determined by AIC
and BIC. Subgroup analyses will be conducted according
to the baseline neuropsychological and fMRI characteristics. Significance level will be set at 0.05 level for the primary outcome and hypothesis; Bonferroni correction
will be applied to all pre-post comparisons for all secondary outcomes, and Benjamini-Hochberg’s procedure
to control false discovery rate at 5% level for all the exploratory analyses. For each outcome measure (primary,
secondary, and exploratory), effect sizes of Cohen’s d
and f will be computed. The effect sizes, along with the
attrition rate at each time point, can be used to guide future study design.

Discussion
In many people with substance use disorders, the lack
of self-awareness on how their brains behave to develop cravings and initiate relapse is a complication
that hampers efforts for abstinence and delays progress in recovery [52, 60]. Given this deficit, this
group of patients are well-equipped to manage their
cravings, and may deny drug-related problems and
underestimate the need for treatment [61, 62]. Enhancing self-awareness by training neurocognitive skills
to help patients to deal with drug craving and other
cognitive consequences of chronic drug use is the aim
of this study that was described in detail above. In
this work, we developed a new neurocognitive rehabilitation program (NEAT) that addresses neurocognitive deficits reported by previous studies in
substance users [11, 63, 64]. The unique aspect of
NEAT is using interactive and engaging structure (including cartoons, brain awareness games, and real-life
scenarios) to train the complex content of neurocognitive functions (e.g., interoception, episodic future
thinking, inhibition) and metacognitive and compensatory skills (e.g., self-monitoring, goal management
training).
We assume that compared to the control intervention,
the patients who receive the NEAT program indicate
positive changes in their roadmap for recovery during
the course of the study. These changes are measured by
using clinical, psychological, and neuropsychological assessments as well as neuroimaging techniques.

Ekhtiari et al. Trials

(2021) 22:330

Fewer studies before have indicated the effectiveness
of metacognitive awareness and cognitive rehabilitation
interventions in alcohol and substance users, in terms of
craving control, improved cognitive functions, and better
treatment outcomes (e.g., treatment adherence, length of
abstinence) [65–71]. Although in all these studies, the
promising results are viewed as a sign of improved regulatory control of top-down system over bottom-up system, but no evidence exists for underlying neural
substrates. Therefore, our study is the first attempt that
applies a broad range of assessments including neural
components to monitor the effect of a cognitive rehabilitation program in substance users. We also consider the
effect of the intervention on real-world functioning (e.g.,
craving management and social and emotional competency) to provide more data on the ecological validity.
Randomized allocation of patients in two groups, employment of an active control condition, blinding outcome assessors, using a fully manualized intervention,
and monitoring the long-term effect of intervention during 1-year follow-up are the most important strengths of
the present study.
In this study, we are expecting to face the following
limitations: (1) participant withdrawal due to schedules
changing or phasing up in the program, (2) scheduling
of other appointments (i.e., visiting a physician) during
Brain Gym times, (3) participants not completing suggested homework or not fill the brain planner, (4) participants absconding from the WiR program or being
terminated from the program, and (5) follow-up problem and lack of data about those participants once they
are discharged from WiR.
To conclude, the effects of a multi-component neurocognitive rehabilitation and awareness program termed
“Neurocognitive Empowerment for Addiction Treatment” (NEAT) on psychological, neurocognitive, and
structural and functional neuroimaging measures will be
examined in a group of female opioids and or methamphetamine users in the context of addiction recovery. If
the results of this study prove the efficacy of NEAT as it
is expected, then a larger trial will be needed to provide
confirmatory evidence to support the next step for transferring the intervention to the clinical practice and embedding NEAT into the routine therapeutic programs as
a supplementary intervention.
Trial status

The present trial is ongoing. Recruitment commenced in
January 2019. Data collection is predicted to be completed by the end of 2021.
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